How Does B12 Injection Work? Mechanism of Action, Per the Research

The short answer

Vitamin B12 (cobalamin) is not a peptide and does not bind a classical cell-surface signalling receptor the way a hormone or a peptide agonist does. Its pharmacology is cofactor pharmacology: the molecule is carried in blood by binding proteins, internalised by endocytic receptors, processed inside the cell, and converted into two coenzyme forms that support two known cobalamin-dependent enzyme reactions in humans. An injected route changes one thing only — how the molecule reaches the bloodstream. It does not change what cobalamin does once it is there.

This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical question, any injectable product, or any decision involving vitamin status. No doses appear anywhere on this page, because none of the three verified sources summarised below supports a dose statement within its title or abstract scope.

What an injection bypasses: the oral absorption chain

Dietary cobalamin reaches the bloodstream through a multi-step chain that standard physiology texts describe in sequence. Each step is a separate potential point of failure, and the practical logic of a parenteral route is that it sidesteps all of them at once.

Because the receptor-mediated ileal step is saturable, oral uptake of a single large load is limited; an injected load is delivered into tissue and taken up into the circulation without passing the cubam step at all. These are descriptions of normal physiology rather than outcomes from the three verified studies cited below, and this page does not attribute them to those studies.

Transport and receptor targets in the bloodstream

Once cobalamin is in the circulation, two carrier proteins dominate the published description of its distribution:

• Transcobalamin (TC, sometimes TC II) — the functionally active carrier. The TC–cobalamin complex, called holotranscobalamin, is the fraction described as available for cellular delivery.
• Haptocorrin (TC I) — binds the majority of circulating cobalamin but is generally described as a reservoir or clearance pathway rather than a delivery route to peripheral tissue.

The nearest thing to a "receptor target" in cobalamin pharmacology is CD320, the transcobalamin receptor expressed on many cell types, which binds holotranscobalamin and internalises it by clathrin-mediated endocytosis. In the kidney, megalin performs an analogous reabsorptive role at the proximal tubule. Neither is a signal-transducing receptor in the G-protein-coupled sense: binding leads to uptake and lysosomal delivery, not to a second-messenger cascade.

Intracellular processing

Inside the lysosome, the carrier protein is degraded and free cobalamin is exported to the cytosol through the LMBD1/ABCD4 export machinery. From there, processing enzymes strip the upper axial ligand and generate the two active coenzymes. This intracellular trafficking pathway is the reason that supplying more cobalamin to the blood does not automatically mean more coenzyme inside a cell: transport, export and processing steps sit in between.

The two established enzyme reactions

Human biochemistry recognises two cobalamin-dependent enzymes. Every established downstream consequence of cobalamin status traces back to one of them.

1. Methionine synthase (cytosol, methylcobalamin)

Methylcobalamin serves as the cofactor for methionine synthase, which transfers a methyl group from 5-methyltetrahydrofolate to homocysteine, producing methionine and regenerating tetrahydrofolate. Two consequences follow in the textbook account: homocysteine is consumed rather than accumulating, and methionine feeds the S-adenosylmethionine (SAM) pool that supplies methyl groups for DNA, RNA, protein and lipid methylation — including the methylation chemistry associated with myelin maintenance. The regeneration of tetrahydrofolate also releases folate back into the one-carbon cycle used for nucleotide synthesis.

2. Methylmalonyl-CoA mutase (mitochondria, adenosylcobalamin)

Adenosylcobalamin is the cofactor for methylmalonyl-CoA mutase, which converts L-methylmalonyl-CoA to succinyl-CoA, feeding propionate-derived carbon from odd-chain fatty acids and certain amino acids into the citric acid cycle. When this reaction is limited, methylmalonic acid accumulates — which is why methylmalonic acid is used in the literature as a functional marker of cobalamin status rather than as a direct measure of blood levels.

These two reactions are the established mechanism. Any further mechanism discussed below is either downstream of them or proposed.

Proposed mechanisms in the cited literature

Neurotrophic signalling: preclinical work

One of the verified sources examined whether cobalamin interacts with neurotrophin signalling. A 2020 report in Neuropharmacology found that acute vitamin B12 supplementation evoked an antidepressant-type response and altered Ntrk-2 — the gene encoding the TrkB receptor for brain-derived neurotrophic factor — in a preclinical model (PMID 32335151). That finding is best read as a mechanistic hypothesis generated in animals: the study linked a cobalamin exposure to a change in a neurotrophin-receptor transcript and a behavioural readout, and researchers did not establish that the same sequence operates in people (PMID 32335151). A plausible bridge to the established biochemistry runs through the methionine/SAM methylation pathway, which can influence gene expression, but this page does not claim that bridge was demonstrated in the cited work.

Local perineural application: a single case report

A second verified source described combined ultrasound-guided perineural vitamin B12 injection and pulsed radiofrequency of the C2 dorsal root ganglion in a patient with C2 postherpetic neuralgia (PMID 42063934). Several limits matter for mechanism reading: it was a single case, the B12 component was delivered alongside a radiofrequency procedure, and the report did not separate the contribution of either component (PMID 42063934). Perineural application also differs conceptually from systemic repletion — the proposed rationale in that setting concerns local nerve tissue rather than correcting a whole-body deficit — and a case report cannot establish a receptor or signalling pathway.

Established versus proposed: a comparison

Safety signals in the cited literature: What Studies Report

Only one of the three verified sources described an adverse event. A 2025 case report in Heliyon described hypokalemic paralysis in an adolescent following dexamethasone and B12 injection, accompanied by a literature review (PMID 39897933). Two mechanistic cautions apply. First, the reported exposure included dexamethasone, a corticosteroid with its own well-described relationship to potassium handling, so the case report did not isolate cobalamin as the cause (PMID 39897933). Second, a single case cannot establish a mechanism of any kind, and the authors presented it as a report rather than as a demonstrated pathway.

The other two verified sources were not safety studies, and this page does not attribute adverse-event findings to them: the Neuropharmacology report examined an antidepressant-type response and Ntrk-2 in a preclinical model (PMID 32335151), and the ultrasound-guided case report described a combined perineural and radiofrequency procedure in one patient (PMID 42063934). Neither was designed to quantify harm, and three papers in total cannot characterise a safety profile. Procedure-related considerations for any injection — injection-site effects, sterile technique, hypersensitivity — fall outside what these three sources examined and belong to a clinician.

What the cited sources do not establish

• No human mechanism for the neurotrophin link. The Ntrk-2 finding was preclinical (PMID 32335151).
• No comparative route data. None of the three verified sources compared injected with oral cobalamin, so no claim about relative uptake between routes is sourced here.
• No dose–response information. Doses are omitted rather than paraphrased, because the verified set does not support them.
• No outcome claims. A single case report (PMID 42063934) and a preclinical model (PMID 32335151) describe observations, not expected results in any individual.

How to read mechanism pages like this one

Mechanism and outcome are different questions. A pathway can be well mapped at the enzyme level — as cobalamin's two reactions are — while the clinical consequences of supplying more of the molecule to a person who is not deficient remain a separate empirical question that these three sources did not answer. Readers comparing sources may find it useful to ask, for each claim: was this a human study or an animal model, was the exposure isolated or combined with another intervention, and did researchers measure a mechanism marker or only an outcome? Applying those three questions to the verified set above places one preclinical signalling report, one combined-intervention case, and one adverse-event case alongside a large body of established cofactor biochemistry that is not itself in dispute.

For background on what vitamin B12 injections are, how the literature categorises their forms, and how the research base is organised, see the overview at PeptideU's B12 injection hub.

References

• Acute vitamin B12 supplementation evokes antidepressant response and alters Ntrk-2 (Neuropharmacology, 2020)
• Hypokalemic paralysis in an adolescent following dexamethasone and B12 injection: A case report and literature review (Heliyon, 2025)
• Combined Ultrasound-guided Perineural Vitamin B12 Injection and Pulsed Radiofrequency of C2 Dorsal Root Ganglion for Treatment of C2 Postherpetic Neuralgia: A Case Report (Journal of Medical Ultrasound, 2026)